Café

© 2026 Longbridge｜Terms of Service Privacy Policy

Tyra Biosciences

TYRA

28.65015.25% ( +3.790 )

Closed: Sep 4, 16:00:00 (EDT)

OverviewOverview OptionsOptions NewsNews PostsPosts FinancialsFinancials ForecastForecast ValuationValuation ShareholdersShareholders ProfileProfile

LongbridgeAI

Top 10 US Stock Gainers (9.4)
Top Gainers&Losers·1 day ago, 10:00 PM
TYRA+15.25%BLTE+13.16%
Tyra Biosciences: Buy Rating Reiterated as SURF302 Data Upside Beckons; 12‑Month Price Target Maintained at $45
Tip Ranks·1 day ago, 03:15 PM
TYRA+15.25%
Tyra Biosciences to present initial Phase 2 SURF302 data for oral dabogratinib in intermediate-risk bladder cancer on Sept. 9
PUBT·1 day ago, 12:01 PM
TYRA+15.25%
Tyra Biosciences to Host Conference Call on Initial Results of Oral Dabogratinib from the SURF302 Phase 2 Study for IR NMIBC on September 9, 2026 | TYRA Stock News
StockTitan·2 days ago, 04:00 AM
TYRA+15.25%
Walleye Capital LLC Acquires Shares of 347,898 Tyra Biosciences, Inc. $TYRA
Market Beat·Aug 15 at 10:32 AM
TYRA+15.25%
Tyra Biosciences, Inc. Stock 12‑Month Price Target Cut to $50.82, Implies 94% Upside
TradingView·Aug 11 at 02:20 PM
TYRA+15.25%
Tyra Biosciences (TYRA) Projected to Announce Earnings on Thursday
Market Beat·Aug 6 at 06:56 AM
TYRA+15.25%
Tyra Biosciences shares are trading lower after the company reported worse-than-expected Q2 EPS results.
benzinga_article·Aug 5 at 01:12 PM
TYRA+15.25%
Tyra Biosciences Q2 FY26 net loss widens to $45.56 million; R&D expenses climb to $39.2 million
PUBT·Aug 4 at 08:22 PM
TYRA+15.25%
Tyra Biosciences | 8-K: FY2026 Q2 Revenue: USD 0
Earnings Watch·Aug 4 at 08:16 PM
TYRA+15.25%
Tyra Bioscience (TYRA) Receives a Buy from Oppenheimer
Tip Ranks·Jun 17 at 11:57 AM
TYRA+15.25%
Tyra Biosciences, Inc. Stock 12‑Month Price Target Cut to $50.8, Implies 96% Upside
TradingView·Jun 10 at 01:20 PM
TYRA+15.25%
Micron Technology To $900? Here Are 10 Top Analyst Forecasts For Wednesday
benzinga_article·Jun 10 at 12:24 PM
- Wall Street analysts have adjusted their price targets for several companies, with notable changes for Surgepays Inc, Cloudflare Inc, and Micron Technology Inc. - Surgepays' target was cut from $5 to $3.5, while Micron's target increased significantly from $400 to $900, maintaining various ratings across these firms. - Other adjustments included Entergy, CECO Environmental, Jazz Pharmaceuticals, J.M. Smucker, Camden Property Trust, Tyra Biosciences, and Teads Holding, reflecting a mix of upgrades and target hikes.
MU+6.10%SJM-1.89%